AI Insight
The U.S. has approved lenacapavir, an injectable HIV prevention medication that requires only twice-yearly dosing, representing a significant advancement over daily oral pills. An Indian pharmaceutical company has committed to manufacturing and distributing generic versions of this long-acting drug to low- and middle-income countries for approximately $40 per year. This pricing structure could dramatically improve access to HIV prevention in regions with the highest disease burden.
Why it matters
The combination of reduced dosing frequency and affordable pricing addresses two major barriers to HIV prevention: medication adherence and cost. This development could significantly reduce new HIV infections globally, particularly in resource-limited settings where daily pill regimens have proven difficult to maintain.
Understand the Science
Indian company pledges to sell injectable lenacapavir in low- and middle-income countries for only $40 a year
Source: U.S. approval of cheap, generic HIV prevention shot may boost global rollout